---
title: "BioCryst Pharmaceuticals Amends Board Appointment Disclosure"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273557568.md"
datetime: "2026-01-23T21:33:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273557568.md)
  - [en](https://longbridge.com/en/news/273557568.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273557568.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/273557568.md) | [繁體中文](https://longbridge.com/zh-HK/news/273557568.md)


# BioCryst Pharmaceuticals Amends Board Appointment Disclosure

BioCryst Pharmaceuticals Inc. has issued an amendment to its previous Form 8-K filing, confirming the completion of its merger with Astria Therapeutics, Inc. As part of this update, BioCryst’s board has appointed Dr. Jill C. Milne to its Compensation and Science Committees, effective as of the merger closing date, January 23, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-000405), on January 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [Astria Therapeutics, Inc. (ATXS.US)](https://longbridge.com/en/quote/ATXS.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [BioCryst Pharmaceuticals, Inc. (BCRX.US)](https://longbridge.com/en/quote/BCRX.US.md)

## Related News & Research

- [Vertex Pharmaceuticals Says US FDA Approves Label Expansion for Alyftrek, Trikafta](https://longbridge.com/en/news/281365753.md)
- [Britain agrees full text of US-UK pharmaceutical trade deal](https://longbridge.com/en/news/281553614.md)
- [Samsung Biologics Acquires GSK's Manufacturing Facility in US](https://longbridge.com/en/news/281465578.md)
- [Investors Purchase High Volume of Call Options on BioCryst Pharmaceuticals (NASDAQ:BCRX)](https://longbridge.com/en/news/281554239.md)
- [Iterum Therapeutics Received Notice of Delisting](https://longbridge.com/en/news/281174211.md)